Pharmacy

More specialty drugs means more management of patient needs and more cooperation

Medication adherence is the common goal of many stakeholders. Pharma is willing to help.

Patent expirations are slowing and other tools are needed to manage costs

Transparent models are fee-based, but do plan sponsors gain anything from such arrangements?

Only 20% of PDPs will offer gap coverage, and even then, most are limited to generics. House and Senate bills aim to help out.

Physicians must evaluate the use of antidepressant medications based on new guidelines from two gynecological organizations

Over the next 20 years, expect to see funky formularies and new drug benefit designs to manage costs

State of the Industry survey results

State of the Industry survey results

Hospital patients who receive dog visits require half the pain medication than patients who don't.

A Cornell study finds that the true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered.

Medco Health Solutions is rumored to be the lead bidder to acquire Aetna's PBM operation.

New vaccines show some potential in therapeutic application. Historically, vaccines have been used in the prevention arenas and priimarily for children.

With plenty of potential information to be communicated among health professionals, pharmacists shouldn't be left out. For many, the pharmacist is the face of healthcare.

Like other health insurers before it, Aetna considers selling off its PBM unit.

Outcomes-based contracting enables risk sharing between plans and manufacturers while also allowing better patient adherence to regimens

Study finds that Americans have limited understanding when it comes to the cost and effectiveness of generic drugs.

While evidence-based plan designs are still evolving, they are improving health outcomes, say experts

The aging population and the huge unmet needs are fueling the focus on biologics, according to a new report from PricewaterhouseCoopers (PwC).

In the wake of healthcare reform, pharmaceutical executives help take charge.

The disparity in coverage between oral and IV chemotherapy medication is a critical issue for patients and is being debated at the national and federal levels.

Wal-Mart pharmacy programs has industry rethinking benefit approaches.

For personalized therapies to be incorporated into a plan's coverage, a commercially insured enrollee would need to stay with the plan for many years, as more expensive therapies require longer member retention to break even, according to Deloitte.

United says it has no plans to follow suit by selling off its pharmacy benefit services. WellPoint will oursource now.

Prescription drug trends show that the underinsured may be voluntarily opting out of compliance due to affordability issues. Lower copayments may be key to curbing this.